Halberd Corporation utilizes a patented extracorporeal treatment method to physically remove harmful pathogens and molecules from the blood, targeting diseases such as COVID-19, PTSD, and cancer. This subtractive therapy approach minimizes the side effects associated with conventional additive treatments, offering a safer alternative for patients with hard-to-cure conditions.
Funding
Funding not disclosed
Founders
Product
Problem
Many hard-to-cure diseases, including COVID-19, PTSD, CTE, and cancer, involve harmful pathogens and molecules circulating in the blood and cerebrospinal fluid. Current treatments often rely on additive therapies that introduce chemicals into the body, which can result in significant and sometimes fatal side effects.
Solution
Halberd Corporation employs a patented extracorporeal treatment method to physically remove disease-causing agents directly from a patient's blood. This subtractive approach, known as Sequential Dialysis Technique, eliminates harmful molecules without the dangerous side effects associated with conventional additive treatments. By targeting the pathophysiologic basis of the disease, Halberd's technology offers a potentially safer and more effective alternative for treating blood-borne and neurological diseases. The company's initial focus is on COVID-19 and similar viral diseases, with future efforts planned for Alzheimer's Disease, PTSD/Traumatic Brain Injury, and cancer.
Target Audience
The primary target audience includes patients suffering from hard-to-cure blood-borne and neurologic diseases, as well as medical professionals seeking safer and more effective treatment options.
Features
- Proprietary Sequential Dialysis Technique for the physical removal of disease-causing agents.
- Subtractive therapy approach minimizes risks associated with conventional additive treatments.
- Extracorporeal treatment applicable to blood-borne and cerebrospinal fluid-related diseases.
- Exclusive licenses to patents related to the extracorporeal treatment.
- Focus on treatments for Covid-19, PTSD, CTE, and Cancer.